{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:03:11Z","timestamp":1791295391571,"version":"4.1.0"},"reference-count":52,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,5,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A plethora of myeloma growth factors (MGFs) has been identified, but their relative importance and cooperation have not been determined. We investigated 5 MGFs (interleukin-6 [IL-6], insulin-like growth factor type 1 [IGF-1], hepatocyte growth factor [HGF], HB\u2013epidermal growth factor [HB-EGF], and a proliferation-inducing ligand [APRIL]) in serum-free cultures of human myeloma cell lines (HMCLs). In CD45\u2212 HMCLs, an autocrine IGF-1 loop promoted autonomous survival whereas CD45+ HMCLs could not survive without addition of MGFs, mainly IGF-1 and IL-6. IGF-1 was the major one: its activity was abrogated by an IGF-1R inhibitor only, whereas IL-6, HGF, or HB-EGF activity was inhibited by both IGF-1R\u2013 and receptor-specific inhibition. APRIL activity was inhibited by its specific inhibitor only. Of the investigated MGFs and their receptors, only expressions of IGF-1R and IL-6R in multiple myeloma cells (MMCs) of patients delineate a group with adverse prognosis. This is mainly explained by a strong association of IGF-1R and IL-6R expression and t(4;14) translocation, but IGF-1R expression without t(4;14) can also have a poor prognosis. Thus, IGF-1\u2013targeted therapy, eventually in combination with anti\u2013IL-6 therapy, could be promising in a subset of patients with MMCs expressing IGF-1R.<\/jats:p>","DOI":"10.1182\/blood-2008-07-170464","type":"journal-article","created":{"date-parts":[[2009,2,18]],"date-time":"2009-02-18T22:24:12Z","timestamp":1234995852000},"page":"4614-4626","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":154,"title":["The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor"],"prefix":"10.1182","volume":"113","author":[{"given":"Anne Catherine","family":"Sprynski","sequence":"first","affiliation":[{"name":"Inserm U847, Montpellier, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[{"name":"Medizinische Klinik V, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany;"},{"name":"Nationales Centrum f\u00fcr Tumorerkrankungen, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Caillot","sequence":"additional","affiliation":[{"name":"ABCell-Bio, Unit for Cellular Therapy, Centre Hospitalier Universitaire (CHU) St Eloi, Montpellier, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"R\u00e9me","sequence":"additional","affiliation":[{"name":"Inserm U847, Montpellier, France;"},{"name":"CHU Montpellier, Institute of Research in Biotherapy, Montpellier, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"John D.","family":"Shaughnessy","sequence":"additional","affiliation":[{"name":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Barlogie","sequence":"additional","affiliation":[{"name":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Seckinger","sequence":"additional","affiliation":[{"name":"Medizinische Klinik V, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Moreaux","sequence":"additional","affiliation":[{"name":"Inserm U847, Montpellier, France;"},{"name":"CHU Montpellier, Institute of Research in Biotherapy, Montpellier, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hundemer","sequence":"additional","affiliation":[{"name":"Medizinische Klinik V, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Jourdan","sequence":"additional","affiliation":[{"name":"Inserm U847, Montpellier, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Mei\u00dfner","sequence":"additional","affiliation":[{"name":"Medizinische Klinik V, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany;"},{"name":"Nationales Centrum f\u00fcr Tumorerkrankungen, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jauch","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Humangenetik, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kar\u00e8ne","family":"Mahtouk","sequence":"additional","affiliation":[{"name":"Inserm U847, Montpellier, France;"},{"name":"CHU Montpellier, Institute of Research in Biotherapy, Montpellier, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alboukadel","family":"Kassambara","sequence":"additional","affiliation":[{"name":"Inserm U847, Montpellier, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Bertsch","sequence":"additional","affiliation":[{"name":"Medizinische Klinik V, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany;"},{"name":"Nationales Centrum f\u00fcr Tumorerkrankungen, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Fran\u00e7ois","family":"Rossi","sequence":"additional","affiliation":[{"name":"Inserm U847, Montpellier, France;"},{"name":"CHU Montpellier, Institute of Research in Biotherapy, Montpellier, France;"},{"name":"Universit\u00e9 Montpellier1, UFR M\u00e9decine, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"Medizinische Klinik V, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany;"},{"name":"Nationales Centrum f\u00fcr Tumorerkrankungen, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Klein","sequence":"additional","affiliation":[{"name":"Inserm U847, Montpellier, France;"},{"name":"CHU Montpellier, Institute of Research in Biotherapy, Montpellier, France;"},{"name":"Universit\u00e9 Montpellier1, UFR M\u00e9decine, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111721395015100_B1","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome.","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"key":"2019111721395015100_B2","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/gcc.20231","article-title":"Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics.","volume":"44","author":"Cremer","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"2019111721395015100_B3","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma.","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"2019111721395015100_B4","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1365-2141.2002.03257.x","article-title":"Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.","volume":"116","author":"Yaccoby","year":"2002","journal-title":"Br J Haematol"},{"key":"2019111721395015100_B5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ccr.2004.10.020","article-title":"Focus on multiple myeloma.","volume":"6","author":"Mitsiades","year":"2004","journal-title":"Cancer Cell"},{"key":"2019111721395015100_B6","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/1097-0142(19920315)69:6<1373::AID-CNCR2820690612>3.0.CO;2-1","article-title":"Interleukin-6 dependence of advanced malignant plasma cell dyscrasias.","volume":"69","author":"Zhang","year":"1992","journal-title":"Cancer"},{"key":"2019111721395015100_B7","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1002\/eji.1830271232","article-title":"Major role of the soluble interleukin-6\/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines.","volume":"27","author":"Gaillard","year":"1997","journal-title":"Eur J Immunol"},{"key":"2019111721395015100_B8","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1084\/jem.179.4.1337","article-title":"Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130.","volume":"179","author":"Zhang","year":"1994","journal-title":"J Exp Med"},{"key":"2019111721395015100_B9","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1046\/j.1365-2141.2000.02364.x","article-title":"Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway.","volume":"111","author":"Ferlin","year":"2000","journal-title":"Br J Haematol"},{"key":"2019111721395015100_B10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1535-6108(04)00050-9","article-title":"Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.","volume":"5","author":"Mitsiades","year":"2004","journal-title":"Cancer Cell"},{"key":"2019111721395015100_B11","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"key":"2019111721395015100_B12","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"key":"2019111721395015100_B13","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1182\/blood-2003-05-1510","article-title":"An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis.","volume":"103","author":"Mahtouk","year":"2004","journal-title":"Blood"},{"key":"2019111721395015100_B14","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1182\/blood.V88.10.3998.bloodjournal88103998","article-title":"Hepatocyte growth factor and its receptor c-met in multiple myeloma.","volume":"88","author":"Borset","year":"1996","journal-title":"Blood"},{"key":"2019111721395015100_B15","first-page":"65","article-title":"Tumor necrosis factor is a survival and proliferation factor for human myeloma cells.","volume":"10","author":"Jourdan","year":"1999","journal-title":"Eur Cytokine Netw"},{"key":"2019111721395015100_B16","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1073\/pnas.0305855101","article-title":"Illegitimate WNT signaling promotes proliferation of multiple myeloma cells.","volume":"101","author":"Derksen","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111721395015100_B17","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1182\/blood.V88.10.3972.bloodjournal88103972","article-title":"Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop.","volume":"88","author":"Gu","year":"1996","journal-title":"Blood"},{"key":"2019111721395015100_B18","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1182\/blood.V99.10.3756","article-title":"Interleukin-21 is a growth and survival factor for human myeloma cells.","volume":"99","author":"Brenne","year":"2002","journal-title":"Blood"},{"key":"2019111721395015100_B19","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1182\/blood-2003-12-4114","article-title":"Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines.","volume":"104","author":"Houde","year":"2004","journal-title":"Blood"},{"key":"2019111721395015100_B20","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.ejca.2005.12.025","article-title":"The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions.","volume":"42","author":"Mitsiades","year":"2006","journal-title":"Eur J Cancer"},{"key":"2019111721395015100_B21","doi-asserted-by":"crossref","first-page":"7289","DOI":"10.1158\/1078-0432.CCR-07-1758","article-title":"Input of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications.","volume":"13","author":"Mahtouk","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2019111721395015100_B22","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"2019111721395015100_B23","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1038\/sj.onc.1205355","article-title":"Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells.","volume":"21","author":"Wang","year":"2002","journal-title":"Oncogene"},{"key":"2019111721395015100_B24","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1182\/blood-2002-09-2907","article-title":"Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma.","volume":"101","author":"Bisping","year":"2003","journal-title":"Blood"},{"key":"2019111721395015100_B25","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood-2003-07-2187","article-title":"Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor alpha [corrected].","volume":"103","author":"Abroun","year":"2004","journal-title":"Blood"},{"key":"2019111721395015100_B26","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.4049\/jimmunol.177.6.4218","article-title":"CD45neg but not CD45pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a murine anti-IGF-1R monoclonal antibody, mAVE1642.","volume":"177","author":"Descamps","year":"2006","journal-title":"J Immunol"},{"key":"2019111721395015100_B27","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3109\/10428199809057614","article-title":"Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and soluble gp130.","volume":"31","author":"Van Zaanen","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"2019111721395015100_B28","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1182\/blood-2002-05-1406","article-title":"Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor.","volume":"100","author":"Standal","year":"2002","journal-title":"Blood"},{"key":"2019111721395015100_B29","first-page":"706","article-title":"CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity.","volume":"90","author":"Bataille","year":"2005","journal-title":"Haematologica"},{"key":"2019111721395015100_B30","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/sj.leu.2403997","article-title":"IGF-1R is overexpressed in poor-prognostic subtypes of multiple myeloma.","volume":"20","author":"Chng","year":"2006","journal-title":"Leukemia"},{"key":"2019111721395015100_B31","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1182\/blood.V83.12.3654.3654","article-title":"Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma.","volume":"83","author":"Zhang","year":"1994","journal-title":"Blood"},{"key":"2019111721395015100_B32","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood.V100.4.1113.h81602001113_1113_1122","article-title":"Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts.","volume":"100","author":"Tarte","year":"2002","journal-title":"Blood"},{"key":"2019111721395015100_B33","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1182\/blood-2005-10-4084","article-title":"Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.","volume":"107","author":"Barlogie","year":"2006","journal-title":"Blood"},{"key":"2019111721395015100_B34","unstructured":"Shaughnessy JD GEO: Gene Expression Profile of Multiple Myeloma, accession number GSE2658. Accessed June 1, 2006 http:\/\/www.ncbi.nlm.nih.gov\/geo\/"},{"key":"2019111721395015100_B35","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/0161-5890(91)90004-4","article-title":"Human recombinant dimeric IL-6 binds to its receptor as detected by anti-IL-6 monoclonal antibodies.","volume":"28","author":"Wijdenes","year":"1991","journal-title":"Mol Immunol"},{"key":"2019111721395015100_B36","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1535-6108(04)00051-0","article-title":"In vivo antitumor activity of NVP-AEW541: a novel, potent, and selective inhibitor of the IGF-IR kinase.","volume":"5","author":"Garcia-Echeverria","year":"2004","journal-title":"Cancer Cell"},{"key":"2019111721395015100_B37","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.1038\/sj.onc.1209699","article-title":"Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma.","volume":"25","author":"Mahtouk","year":"2006","journal-title":"Oncogene"},{"key":"2019111721395015100_B38","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1182\/blood-2002-09-2801","article-title":"A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH\/MMSET fusion transcript.","volume":"101","author":"Santra","year":"2003","journal-title":"Blood"},{"key":"2019111721395015100_B39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-2105-9-16","article-title":"A new method for class prediction based on signed-rank algorithms applied to Affymetrix microarray experiments.","volume":"9","author":"Reme","year":"2008","journal-title":"BMC Bioinformatics"},{"key":"2019111721395015100_B40","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1634\/stemcells.2006-0352","article-title":"A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas.","volume":"25","author":"Assou","year":"2007","journal-title":"Stem Cells"},{"key":"2019111721395015100_B41","first-page":"57","article-title":"Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle: a possible model for the cooperation of myeloma cell growth factors.","volume":"16","author":"Jourdan","year":"2005","journal-title":"Eur Cytokine Netw"},{"key":"2019111721395015100_B42","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1182\/blood.V88.6.2250.bloodjournal8862250","article-title":"Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines.","volume":"88","author":"Georgii-Hemming","year":"1996","journal-title":"Blood"},{"key":"2019111721395015100_B43","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.4049\/jimmunol.151.4.1811","article-title":"Insulin and IGF-1 increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI-8226.","volume":"151","author":"Freund","year":"1993","journal-title":"J Immunol"},{"key":"2019111721395015100_B44","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1038\/sj.onc.1208536","article-title":"Expression of EGF-family receptors and amphiregulin in multiple myeloma: Amphiregulin is a growth factor for myeloma cells.","volume":"24","author":"Mahtouk","year":"2005","journal-title":"Oncogene"},{"key":"2019111721395015100_B45","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2004-11-4512","article-title":"The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature.","volume":"106","author":"Moreaux","year":"2005","journal-title":"Blood"},{"key":"2019111721395015100_B46","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/sj.leu.2401632","article-title":"Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors.","volume":"14","author":"Gu","year":"2000","journal-title":"Leukemia"},{"key":"2019111721395015100_B47","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1182\/blood-2006-08-043232","article-title":"Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.","volume":"109","author":"Mahtouk","year":"2007","journal-title":"Blood"},{"key":"2019111721395015100_B48","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/nrd2359","article-title":"Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer.","volume":"6","author":"Clemmons","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"2019111721395015100_B49","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1182\/blood-2004-06-2141","article-title":"Heparanase promotes the spontaneous metastasis of myeloma cells to bone.","volume":"105","author":"Yang","year":"2005","journal-title":"Blood"},{"key":"2019111721395015100_B50","doi-asserted-by":"crossref","first-page":"13326","DOI":"10.1074\/jbc.M611259200","article-title":"Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis.","volume":"282","author":"Yang","year":"2007","journal-title":"J Biol Chem"},{"key":"2019111721395015100_B51","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1200\/JCO.2007.15.9319","article-title":"Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma.","volume":"26","author":"Lacy","year":"2008","journal-title":"J Clin Oncol"},{"key":"2019111721395015100_B52","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.V86.2.685.bloodjournal862685","article-title":"Biologic effects of anti-interleukin-6 (IL-6) murine monoclonal antibody in advanced multiple myeloma.","volume":"86","author":"Bataille","year":"1995","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/113\/19\/4614\/1486205\/zh801909004614.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/113\/19\/4614\/1486205\/zh801909004614.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T22:37:07Z","timestamp":1684881427000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/113\/19\/4614\/25985\/The-role-of-IGF1-as-a-major-growth-factor-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,7]]},"references-count":52,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2009,5,7]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2008-07-170464","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,7]]}}}